Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, Mcgill JB, Mcmurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA (2019)
Publication Type: Journal article
Publication year: 2019
Book Volume: 73
Pages Range: 309-315
Journal Issue: 3
DOI: 10.1053/j.ajkd.2018.10.006
Rationale & Objective: Evidence from clinical trials to guide patient preparation for maintenance dialysis therapy is limited. Although anemia is associated with mortality and cardiovascular (CV) disease in individuals initiating maintenance dialysis therapy, it is not known if treatment of anemia before dialysis therapy initiation with erythropoiesis-stimulating agents alters outcomes.
APA:
Mc Causland, F.R., Claggett, B., Burdmann, E.A., Chertow, G.M., Cooper, M.E., Eckardt, K.-U.,... Pfeffer, M.A. (2019). Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 73(3), 309-315. https://doi.org/10.1053/j.ajkd.2018.10.006
MLA:
Mc Causland, Finnian R., et al. "Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)." American Journal of Kidney Diseases 73.3 (2019): 309-315.
BibTeX: Download